BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Akeso Doses First Patient in Phase Ia Trial of AK146D1, the World’s First Bispecific ADC Targeting Trop2 and Nectin4

Akeso, Inc. (9926.HK) ("Akeso" or the "Company") has announced the successful enrollment of the first patient in its Phase Ia clinical trial for AK146D1, a...

July 04, 2025 | News

Ascletis Doses First Participants in U.S. Phase IIa Trial of Oral Small Molecule GLP-1 Agonist ASC30 for Obesity

- First participants with obesity or overweight with at least one weight-related comorbidity have been dosed in a ...

July 03, 2025 | News

Mabwell Grants Qilu Pharmaceutical Greater China Rights to Next-Generation Long-Acting G-CSF Albipagrastim Alfa

Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced its wholly-owned subsidiary T-mab has entered into an ag...

June 30, 2025 | News

XtalPi Expands AI-Driven Drug Discovery Collaboration with Pfizer to Develop Next-Generation Molecular Modeling Platform

XtalPi (2228.HK), a leading global technology company in integrating artificial intelligence (AI) and robotics to advance the discovery of groundbreaking m...

June 30, 2025 | News

CanSinoBIO’s iPneucia® Vaccine Targets Deadly Pneumococcal Threat in Chinese Children with Precision and Safety

Pneumonia is a form of acute respiratory infection, that is common in all age groups and can cause mild to life-threatening illness. It is also the single ...

June 23, 2025 | News

Immuno Cure and PharmaJet Partner on Needle-Free HIV Therapeutic Vaccine Study in Hong Kong

Immuno Cure BioTech ("Immuno Cure"), a clinical-stage biotechnology group based in Hong Kong Science Park, is pleased to announce its upcoming collaboratio...

June 20, 2025 | News

VivaVision Receives Positive FDA Feedback on VVN461LD Phase 2 Trial for Ocular Inflammation

VivaVision Biotech (VivaVision), a late clinical-stage, privately-held biotech company focused on developing innovative ophthalmic drugs, announced today t...

June 10, 2025 | News

GenEditBio Doses First Patient in World's First In Vivo CRISPR Trial for TGFBI Corneal Dystrophy

GenEditBio Limited ("GenEditBio"), a clinical-stage biotechnology start-up company focusing on genome editing therapeutic solutions through the discovery o...

June 09, 2025 | News

Akeso’s Cadonilimab Secures NMPA Approval for First-Line Treatment of Cervical Cancer

Akeso, Inc. is pleased to announce that the National Medical Products Administration (NMPA) has approved the company's first- in-class PD-1/CTLA-4 bispecif...

June 05, 2025 | News

Excyte Doses First Patient in Global Trial of YK012, the First T Cell Engager for Primary Membranous Nephropathy

Excyte, a global clinical-stage biotechnology company, announced first patient has been dosed for YK012, the world’s first patient T cell engager tha...

June 03, 2025 | News

Concord Healthcare Unveils China’s First Proton Therapy-Focused Large Language Model

Concord Healthcare Group Co., Ltd. ("Concord Healthcare"), a subsidiary of Concord Medical Services Holdings Limited (the "Company") (NYSE: CCM), whic...

June 02, 2025 | News

Hong Kong Strengthens Position as Global Healthcare Investment Hub with Over 1,000 Business Meetings at ASGH and Medical Fair

Over 1,000 investment and business matching meetings lined up underscoring Hong Kong's role as a healthcare investment hub - ASGH brought toget...

May 29, 2025 | News

United Imaging and HKSH Medical Group Unite to Set New Standards in Medical Imaging Excellence

United Imaging and HKSH Medical Group announced on Monday the signing of a Memorandum of Understanding (MOU), marking a significant step forward in fosteri...

May 28, 2025 | News

HKSH Medical Group Strengthens Global Healthcare Partnerships with New Collaboration on Imaging Innovation

The HKSH Medical Group (HKSH) has for over a century been committed to acquiring the state-of-the-art, world-class technology and facilities to deliver exc...

May 28, 2025 | News

Stay Connected